30 May 2024
MicroSalt PLC
("MicroSalt", "the Company" or the
"Group")
Final Results for the year ended 31
December 2023
and Notice of Annual General
Meeting
MicroSalt Plc, (AIM: SALT) a
company commercialising a patented technology to produce
full-flavour low-sodium salt, is pleased to announce its first set
of full year results following the successful admission of the
Company to the AIM market of the London Stock Exchange in February
2024.
Highlights:
· 2023
marked significant progress for Microsalt's efforts with
larger-volume B2B customers and the launch of Microsalt®
salt-shakers
· Initial purchase orders totalling 29 mT of Microsalt was
received from Customer B, the Mexican business of one of the
largest beverage and snack food companies in the world, who
launched an existing popular product using MicroSalt in their
market in Q4 2023
· Partnership
announced with Customer A, a US Fortune 500 pharmacy/food retailer,
for the development and sale of low-sodium solutions across the
retailer's extensive line of private branded snack offerings. This
is expected to lead to placement of several of their snacks using
MicroSalt® in lieu of traditional salt, beginning with 800 stores
in Q4 2023 with the potential to expand across more than 7,000
store locations in the medium term
· FY
2023 revenue of US$ 0.6m (2022: US$ 0.6m) and net loss
of US$ 3.5m (2022: US$2.5m) reflecting efforts focused
on R&D and preparation for the launch of the first two major
food manufacturing customers within the Company's B2B
solution
· 2024 set to be a
key year where MicroSalt is expected to receive recurring
commercial volume purchase orders for its bulk product, whilst
acknowledging the rollout of MicroSalt across new and/or further
B2B product lines has been slower than hoped during the current
year to date
· Strong pipeline
with significant volume customer prospects at advanced stages with
a range of national and multi-national companies with scope for
MicroSalt to be nominated as a supplier on larger product lines
once established with these key customers
· Important R&D
projects to be undertaken in 2024 focused on three new iterations
of MicroSalt to expand its effectiveness across additional food
formulas and environments
Rick Guiney, CEO of MicroSalt
commented:
"This has been a transformational year for MicroSalt and with
continued evidence of the timeliness and essential nature of its
products as it emerged as a recognised and preferred choice for
product reformulation globally. Our geographic outreach is
expanding all the time, now with inroads into Asia, Australia,
South Africa, the UK, Germany, Canada and Latin America with a
resultant boost to our sales pipeline. Furthermore, our consumer
products including SaltMe crisps and MicroSalt shakers
have successfully provided a low-sodium alternative for households
worldwide, cementing our brand as an essential, generation-spanning
choice. I am delighted that we can look ahead with the utmost
confidence and in eager anticipation of further successes awaiting
us".
Notice of
Annual General Meeting
The Annual General Meeting ("AGM") of MicroSalt
Plc will be held at the offices of Bird & Bird LLP, 12 New
Fetter Lane, London EC4A 1JP on 21 June 2024 at 12.30 p.m. (British
Summer Time). The annual report and the formal notice of the 2023
AGM will be posted to shareholders on 30 May 2024.
The notice of AGM will be available to review on
the Company's website at: www.microsalt.co
For
more information, please visit www.microsaltinc.co,
follow on X @microSaltPLC or contact:
MicroSalt plc
|
Via Flagstaff PR
|
Rick Guiney, CEO
|
|
|
|
Zeus (Nominated
Adviser and
Broker)
David Foreman / James Edis (Investment
Banking)
Dom King (Corporate Broking), Rupert Woolfenden
(Sales)
|
+44 (0)20 3829 5000
|
|
|
|
|
Flagstaff PR (Financial
PR)
|
+44 (0)20 7129 1474
|
Tim Thompson / Alison Allfrey / Anna
Probert
microsalt@flagstaffcomms.com
|
|
Notes to Editors
MicroSalt® produces a patented
full-flavour, low-sodium salt for food manufacturers and
consumers.
MicroSalt is a major potential
disruptor in the food market, thanks to its micron sized particles
which deliver the same sense of saltiness to a wide range of foods
but with approximately 50% less sodium. Excess sodium consumption
is a significant contributor to cardiovascular disease and
MicroSalt's solution meets the rising demand for healthier
alternatives to traditional salt. The WHO has set a target for
reducing global sodium intake by 30% by 2025, which it estimates
will save 7 million lives by 2030.
Each year, cardiovascular disease
costs the UK £19 billion - if the average salt intake was reduced
by one gram per day, it has been estimated that 4,147 lives and
£288 million would be saved each year in the UK. As a nation, the
UK consumes 183 million kilograms of salt each year, and 70% of the
typical person's sodium intake is hidden in processed
foods.
Operational since 2018, MicroSalt
uses a patent-protected technology which helps create high barriers
to entry within the reduced-sodium salt market.
The Directors believe that MicroSalt
is well positioned to capture growth in the low sodium market,
which is expected to grow exponentially, and that there is also
scope to enter the larger salt market.
Chair's Statement
I am delighted to announce, on behalf
of the Board, MicroSalt's first set of full year results following
the successful admission of the Company to the AIM market of the
London Stock Exchange in February 2024. I would like to take this
opportunity to thank our longer-term shareholders for their ongoing
support, in particular Tekcapital plc for their early-stage funding
and advice, and to welcome all our new shareholders. I would also
like to thank our employees, suppliers,
customers, and everyone who has and is supporting the business and
in delivering its successful IPO.
Strategy
MicroSalt is a company focused on
commercialising a patented technology to produce full-flavour,
low-sodium salt for food manufacturers and consumers. The food
industry is focused on developing and providing better-for-you
products that taste great and reduce sodium intake. The reason for
this is that excess sodium consumption contributes to
cardiovascular disease, a leading cause of premature death
globally. To address this problem, MicroSalt has developed a
patented process for producing micron-sized salt crystals that
provide all of the flavour of salt with roughly half of the sodium
for topical food applications. MicroSalt
has developed what we believe to be the world's smallest edible
salt crystals with its patented MicroSalt®. With MicroSalt®,
companies can make full flavour snacks and prepared meals with the
same saltiness as traditional foods yet with half of the sodium.
MicroSalt® dissolves faster, is all natural, non-GMO, Kosher and
does not contain any of the additives or salt substitutes found in
other sodium reduction products.
Board and Governance
As a Board, we are committed to
promoting the highest standards of corporate governance and
ensuring effective communication with shareholders. We remain
focused on ensuring the Company delivers on its long-term growth
strategy and is run in a sustainable and socially responsible
manner with a strong level of governance oversight from the Board
of Directors.
Outlook
We are excited about 2024 as the year where we
see MicroSalt receiving recurring commercial volume purchase orders
for its bulk product. The Group currently has
various significant volume customer prospects at advanced stages
with a range of national and multi-national companies. The nature
and size of these existing and potential customers businesses is
that once MicroSalt has been nominated as a supplier on one product
line, we expect further nominations across multiple other, and
likely much larger product lines of that
customer.
We also anticipate more investment into growth
of our MicroSalt® shakers and its establishment as the generational
salt used at home.
Judith Batchelar
Chair
Chief Executive Officer's statement
Introduction
The Company's mission is to reduce excess sodium
consumption which significantly contributes to hypertension and
heart disease, by providing a full-flavour salt with approximately
50% less sodium than traditional salt for food manufacturers and
consumers.
To achieve this, the Group has developed a
patent protected and scalable manufacturing process that produces a
salt crystal that is approximately 100 times smaller than
traditional salt. Due to its micron sized particles, MicroSalt has
improved adhesion to food (compared with traditional salt crystals)
and dissolves much faster on the tongue, thereby delivering the
same sense of saltiness as traditional snacks but using
approximately half the amount of sodium.
2023 was without doubt, a pivotal year for
MicroSalt, marked by foundational efforts and strategic growth. It
was indeed a year of building-akin to preparing a snowball before
letting it roll downhill. As we promote our vision of a healthier
future through reduced sodium in today's diets, we are discovering
more and more possibilities and commercial
opportunities.
Our leadership team's steadfast commitment has
continually affirmed that our products are timely and essential. In
2023, MicroSalt emerged as a recognised and preferred choice for
product reformulation globally. Our outreach initiatives have
extended across continents, with inroads in Asia, Australia, South
Africa, the UK, Germany, Canada, and Latin America, all of which
have boosted our sales pipeline. Moreover, our consumer products,
including SaltMe Potato Chips and MicroSalt Shakers, have
successfully provided a low-sodium alternative for households
worldwide, cementing our brand as an essential, generation-spanning
choice.
By way of reminder, our primary B2B
opportunities during 2023 existed with:
· Customer A, a US
Fortune-500 pharmacy/food retailer;
· Customer B, the
Mexican business of Customer C; and
· Customer C, one
of the largest beverage/snack companies in the world;
and
· Customer D, one
of the largest global bakery companies.
Looking ahead, we approach the future with
utmost confidence and eagerly anticipate the successes that await
us.
Financial summary
The Company's revenue of US$0.6m (2022: US$0.6m)
and net loss of US$3.5m (2022: US$2.5m) are both reflective of
efforts focused on R&D and preparation for the launch of the
first two major food manufacturing customers within the Company's
B2B solution. Translation of our B2B pipeline of opportunities was
always going to take time, but commercial purchase orders were
received from Customer B, with 29 mT of MicroSalt being delivered
to them in late 2023. Accordingly, most of the revenue in 2023 was
D2C (Direct to Consumer). With initial B2B orders received in the
latter part of 2023 and multiple other B2B opportunities in various
stages of testing/customer acceptance procedures, combined with IPO
readiness preparation, the Company did not invest significantly
into its D2C sales throughout the year.
Inventories increased to US$0.6m (2022:
US$0.2m), predominantly due to an increase in raw materials, again
in preparation for the expected bulk orders from the Company's
first two major food manufacturing B2B customers (Customers A and
B).
Trade and other receivables increased to US$1.3m
(2022: US$0.2m), predominantly due to US$0.7m of deferred costs in
relation to the IPO being included in prepayments at year
end.
Trade and other payables increased to US$1.7m
(2022: US$0.2m), predominantly due to increases in trade payables
and amounts owed to related parties.
Borrowings also increased to US$2.5m (2022:
US$0.2m), predominantly due to increases in convertible loan
notes.
Operations
summary
A key focus of the business during 2023 was of
our larger-volume B2B opportunities with a number of multinational
FMCG companies and food manufacturers. The majority of these
opportunities have now passed through the R&D phase as well as
production testing and then consumer testing. In particular, the
Group is now an approved supplier of Customer B and Customer C,
which although separate entities, operate under the same group.
Customer B launched an existing popular product now using MicroSalt
in the Mexican market in the fourth quarter of 2023. In 2023, 29 mT
of MicroSalt was delivered to Customer B. Customer B also provided
annualised volume targets, albeit on a non-binding basis.
Furthermore, the Company began negotiating a purchasing agreement
and joint development agreement with Customer C which is expected
to be executed in the second half of 2024.
Other selected milestones achieved during 2023
include:
•
Partnership announced with Customer A for the development and
execution of low-sodium solutions across the retailer's extensive
line of private branded snack offerings. This will lead to
placement of several of their snacks using MicroSalt® in lieu of
traditional salt, beginning with 800 stores in Q4 2023 with the
potential to expand across more than 7,000 store locations in the
medium term;
•
Agreement with supermarket chain, Giant Food of Maryland LLC,
one of the most respected food retailers in the mid-Atlantic United
States, to carry MicroSalt's new saltshakers across its 160
stores;
•
Continued sales expansion of SaltMe! crisps and MicroSalt
shakers with new placements in over 400
additional U.S. retail stores.
•
Agreement with US Salt LLC for the distribution and
delivery of MicroSalt's low-sodium solutions.
Sales and
marketing
MicroSalt attended a number of US based and
international food shows, which has been the core focus of its
sales and outreach efforts. In 2024, the Company plans to attend at
least 12 food shows globally, including events in Frankfurt, Paris,
Shanghai, Dubai, and Stockholm. These are in addition to the major
industry events in the US market The Company also invests actively
into brand awareness and social media campaigns relevant especially
to its D2C business. The Company also appointed the U.K. celebrity
chef Jack Stein as a Brand Ambassador.
Intellectual
property
Subsequent to the year end, in May 2024 the
United States Patent and Trademark Office granted and issued
MicroSalt's patent entitled 'Low Sodium Salt
Composition'.
Political/regulatory
update
The World Health Organisation ("WHO") has set a
target of reducing global sodium intake by 30% by 2025, which it
estimates will save 7 million lives by 2030. WHO research also
found that every US$1 spent on sodium reduction translates to US$12
in healthcare cost savings for treating cardiovascular disease.
Governmental pressure continues to increase with new regulations in
Canada for 2025. Additionally, local dieticians and purchasing
authorities are taking action, regardless of any legal mandates, to
lower sodium.
Current trading
and outlook
MicroSalt made significant progress in 2023, the
rollout of MicroSalt across new and/or further product lines across
Customers A, B, C and D has been slower than hoped during 2024 so
far. However, this statement does not reflect the significant
progress regarding positive trials undertaken during this year so
far, or indeed the deepening of knowledge and relationships
MicroSalt has with our key B2B customers and target customers.
Furthermore, we are increasingly confident of announcing further
commercial volume orders with Customer B in particular, in the
third quarter of 2024.
In addition to our focus on B2B sales of
MicroSalt® to food manufacturing companies where the Company has
made substantial progress, MicroSalt has launched its low sodium
salt in saltshakers during 2023. Approximately 400 supermarkets now
carry these better-for-you saltshakers. The Company also made
significant progress towards finalisation of its IPO on the AIM
Market of the London Stock Exchange, which completed in February
2024.
Beyond our primary focus on sales and marketing,
I'm pleased to advise of several other developments during 2024,
including:
- New
employees, namely a new UK sales manager and a US based group
financial controller;
- R&D
projects focused on three new iterations of MicroSalt to expand its
effectiveness across various additional food formulas and
environments. We expect this should lead to entrance into
additional markets and potential applications for MicroSalt both
short and long term.
These are just a taster of the developments of
the Group we expect to continue into the second half of 2024 and
beyond.
Finally, I must recognise, on behalf of the
Board, our sincere thanks to all stakeholders in the business who
have supported us and are making possible the achievement of our
mission and objectives. To that end, we note the strong share price
performance since IPO which recently enabled the Company to
exercise its right to call the outstanding warrants in the Company,
granted at the time of the IPO. In our opinion, the support of our
shareholders is justified, and whilst I would have liked to have
announced further commercial volume orders during the year to date,
we are excited about 2024 as the year where we see MicroSalt
receiving recurring commercial volume purchase orders for its bulk
product.
Rick Guiney
Chief Executive Officer
Consolidated statement of profit or loss and other
comprehensive income
|
Note
|
Year ended
31 December
2023
US$'000
|
|
Year ended
31 December
2022
US$'000
|
|
|
|
|
|
|
Revenue
|
4
|
574
|
|
638
|
Cost of sales
|
|
(724)
|
|
(441)
|
Gross (loss)/profit
|
|
(150)
|
|
197
|
|
|
|
|
|
Other operating income
|
5
|
120
|
|
30
|
Administrative expenses
|
|
(3,318)
|
|
(2,639)
|
Operating loss
|
|
(3,348)
|
|
(2,412)
|
|
|
|
|
|
Finance expense
|
10
|
(131)
|
|
(67)
|
Loss before taxation
|
|
(3,479)
|
|
(2,479)
|
Taxation
|
11
|
-
|
|
-
|
Loss for the year
|
|
(3,479)
|
|
(2,479)
|
|
|
|
|
|
Loss for the year attributable to:
|
|
|
|
|
Owners of the parent
|
|
(3,479)
|
|
(1,940)
|
Non-controlling interests
|
|
-
|
|
(539)
|
|
|
(3,479)
|
|
(2,479)
|
|
|
|
|
|
Other comprehensive income
|
|
|
|
|
Items that may
or may not be recognised in profit or loss:
|
|
|
|
|
Foreign currency translation
differences
|
|
6
|
|
-
|
Total comprehensive income
|
|
(3,473)
|
|
(2,479)
|
|
|
|
|
|
Total comprehensive loss attributable
to:
|
|
|
|
|
Owners of the parent
|
|
(3,473)
|
|
(1,940)
|
Non-controlling interests
|
23
|
-
|
|
(539)
|
|
|
(3,473)
|
|
(2,479)
|
|
|
|
|
|
Loss per share for loss attributable to the
owners
|
|
|
|
|
Basic and diluted loss per share
(US$)
|
12
|
(0.39)
|
|
(166.61)
|
|
|
|
|
|
Consolidated statement of financial position
Company Number 10061337
|
Note
|
As at
31 December
2023
US$'000
|
|
As at
31 December
2022
US$'000
|
|
Assets
|
|
|
|
|
Current assets
|
|
|
|
|
Inventories
|
15
|
568
|
|
208
|
Trade and other receivables
|
16
|
1,259
|
|
221
|
Cash and cash equivalents
|
17
|
117
|
|
91
|
Total current assets
|
|
1,944
|
|
520
|
|
|
|
|
|
Non-current assets
|
|
|
|
|
Property, plant & equipment
|
14
|
8
|
|
-
|
Intangible assets
|
13
|
321
|
|
147
|
Total non-current assets
|
|
329
|
|
147
|
|
|
|
|
|
Total assets
|
|
2,273
|
|
667
|
|
|
|
|
|
Liabilities
|
|
|
|
|
Current liabilities
|
|
|
|
|
Trade and other payables
|
18
|
1,745
|
|
165
|
Total current liabilities
|
|
1,745
|
|
165
|
|
|
|
|
|
Non-current liabilities
|
|
|
|
|
Borrowings
|
19
|
2,524
|
|
170
|
Total non-current liabilities
|
|
2,524
|
|
170
|
|
|
|
|
|
Total liabilities
|
|
4,269
|
|
335
|
|
|
|
|
|
Net (liabilities)/assets
|
|
(1,996)
|
|
332
|
|
|
|
|
|
Equity
|
|
|
|
|
Share capital
|
20
|
73
|
|
-
|
Share premium
|
20
|
-
|
|
1,121
|
Share-based payment reserve
|
|
1,060
|
|
488
|
Capital contribution reserve
|
|
500
|
|
2,452
|
Accumulated losses
|
|
(3,635)
|
|
(3,999)
|
Translation reserve
|
|
6
|
|
-
|
|
|
(1,996)
|
|
62
|
|
|
|
|
|
Non-controlling interests
|
23
|
-
|
|
270
|
|
|
|
|
|
Total equity
|
|
(1,996)
|
|
332
|
|
|
|
|
|
|
|
|
|
|
Consolidated statement of cash flows
|
|
Year ended
31 December
2023
US$'000
|
|
Year ended
31 December
2022
US$'000
|
Note
|
|
Cash flows from operating activities
|
|
|
|
|
Loss before income tax
|
|
(3,479)
|
|
(2,479)
|
Depreciation of
property, plant and equipment
|
14
|
1
|
|
-
|
Amortisation of
intangible assets
|
|
6
|
|
2
|
Share based payment
expense
|
|
572
|
|
379
|
Finance
expense
|
10
|
131
|
|
67
|
|
|
(2,769)
|
|
(2,031)
|
|
|
|
|
|
(Increase) / decrease in inventories
|
15
|
(360)
|
|
24
|
Increase in trade and other
receivables
|
16
|
(1,038)
|
|
(76)
|
Increase in trade and other payables
|
18
|
1,580
|
|
111
|
Net cash used in operating activities
|
|
(2,587)
|
|
(1,972)
|
|
|
|
|
|
Cash flows from investing activities
|
|
|
|
|
Purchase of intangible assets
|
13
|
(180)
|
|
(116)
|
Payments to acquire
property, plant and equipment
|
14
|
(9)
|
|
-
|
Net cash used in
investing activities
|
|
(189)
|
|
(116)
|
|
|
|
|
|
Cash flows from
financing activities
|
|
|
|
|
Issue of
shares
|
|
73
|
|
-
|
Proceeds from
borrowings
|
|
2,723
|
|
1,652
|
Investment by
non-controlling interests
|
|
-
|
|
509
|
Net cash from
financing activities
|
|
2,796
|
|
2,161
|
|
|
|
|
|
|
|
|
|
|
Increase in cash and cash equivalents
|
17
|
20
|
|
73
|
Cash and cash equivalents at beginning of
year
|
|
91
|
|
18
|
Effect of foreign exchange rate
changes
|
|
6
|
|
-
|
Cash and cash equivalents at end of
year
|
|
117
|
|
91
|
|
|
|
|
|
|
|
|
|
|
Notes to the consolidated financial
statements
1. General
information
MicroSalt Plc (the "Company") is a private
company limited by shares and registered and incorporated in
England and Wales. The registered office is 12 New Fetter Lane,
London, United Kingdom, EC4A 1JP.
The principal activity of the Company together
with its subsidiary undertaking (the "Group") is that of the
development and sale of low sodium salt and snack foods.
2. Accounting
policies
2.1
Basis of preparation
The consolidated financial statements are for
the year ended 31 December 2023. They have been prepared in
accordance with UK-adopted International Accounting Standards
("IFRS"). The prior year consolidated information for year ended 31
December 2022 was included in the historical financial information
in the admission document to AIM, which was deemed to be the
first-year accounts under IFRS. The adoption of IFRS did not lead
to changes in the recognition of measurement of transactions or
balances, and consequently no reconciliation required under IFRS 1
was presented in the historical financial information. These are
the first company financial statements prepared under IFRS, the
adoption of IFRS did not lead to changes in the recognition of
measurement of transactions or balances, and consequently no
reconciliation required under IFRS 1 has been included.
The financial statements have been prepared
under the historical cost convention. The measurement bases and
principal accounting policies of the Group are set out
below.
New standards,
amendments and interpretations
Standards and
interpretations adopted during the year
Information on new standards, amendments and
interpretations that are relevant to the Group annual report and
accounts is provided below:
· Deferred Tax related to Assets and Liabilities arising from a
Single Transaction - amendments to IAS 12
· Disclosure of Accounting Policies - amendments to IAS 1 and
IFRS Practice Statement 2
· Definition of Accounting Estimates - amendments to IAS
8
The Group did not have to change its accounting
policies or make retrospective adjustments as a result of adopting
these new standards and amendments and they did not have a material
impact.
Standards,
amendments and interpretations that are not yet
effective
Certain new standards, amendments to standards,
and interpretations which have been issued by the IASB that are
effective in future accounting periods that the Group has decided
not to adopt early. These standards, amendments or interpretations
are not expected to have a material impact on the Group.
2.2
Going concern
The Directors have assessed the ability of the
Group to continue as a going concern using cash flow forecasts. The
Group meets its day to day working capital requirements through
financing provided by Tekcapital PLC primarily via the issue of
convertible loan notes and subsequent to the year end, cash raised
from the admission to AIM. The Directors are satisfied that there
are sufficient resources to continue in business for the
foreseeable future and for at least 12 months from the date of
signing these financial statements.
Notes to the consolidated financial statements
(continued)
2.
Accounting policies (continued)
Furthermore, the Directors are not aware of any
material uncertainties that may cast significant doubt upon the
Group's ability to continue as a going concern. They are mindful of
the ongoing conflict in Russia and Ukraine and rising costs of
inflation but are confident they have appropriate plans in place to
mitigate any such risk in relation to this. Therefore, the
financial statements continue to be prepared on the going concern
basis.
2.3
Revenue recognition
IFRS 15 "Revenue from Contracts with Customers"
is a principle-based model of recognising revenue from contracts
with customers. The model comprises five steps with revenue being
recognised when control over goods and services are transferred to
the customer.
The Group's revenue consists of product sales.
Revenue is recognised when the Group delivers a product to the
customer. Payment of the transaction price is due immediately when
the customer purchases the product and takes delivery or in the
case of certain business to business transactions on credit
terms.
Revenue is measured at the fair value of the
consideration received, excluding discounts, rebates and sales
taxes or duty.
2.4
Basis of consolidation
The consolidated financial statements present
the results of the Company and its subsidiaries as if they form a
single entity.
Profit or loss and each component of other
comprehensive income are attributed to the equity holders of the
parent of the Group and to the non-controlling interests, even if
this results in the non-controlling interests having a deficit
balance. When changes in ownership in a subsidiary do not result in
a loss of control, the non-controlling shareholders' interests are
initially measured at the non-controlling interests' proportionate
share of the subsidiaries net assets. Subsequent to this, the
carrying amount of non-controlling interests is the amount of those
interests at initial recognition plus the non-controlling
interests' share of subsequent changes in equity.
When necessary, adjustments are made to the
financial information of subsidiaries to bring their accounting
policies in line with the Group's accounting policies. All
intra-group assets and liabilities, equity, income, expenses and
cash flows relating to transactions between members of the Group
are eliminated in full on consolidation.
2.5
Other operating income and grants
Other operating income represents all other
income received by the Group. This includes
R&D Expenditure Credits which are a form of government
grant.
Government grants are recognised at their fair
value where there is a reasonable assurance that the grant will be
received, and the Group will comply with all attached conditions.
Government grants relating to costs are deferred and recognised in
the statement of profit or loss and other comprehensive income over
the period necessary to match them with the costs that they are
intended to compensate.
The grant income received has been accounted for
in accordance with IAS 20 'Accounting for Government Grants and
Disclosure of Government Assistance' and is shown in other
operating income in the statement of profit or loss and other
comprehensive income whilst research and development expenditure is
shown gross of grant income.
2.6
Finance expense
Finance expense comprises of interest payable on
convertible loan notes which are expensed in the period in which
they are incurred and reported in finance costs.
Notes to the consolidated financial statements
(continued)
2 Accounting policies
(continued)
2.7
Foreign currency translation
The functional currency of the Company is GB
Pounds Sterling. For the purposes of the consolidated Interim
Financial Information, the results and financial position of the
Company and its subsidiary are presented in US Dollars which is the
Group's presentational currency.
Transactions in foreign currencies are recorded
at the rate ruling at the date of the transaction. Monetary assets
and liabilities denominated in foreign currencies are retranslated
at the rate of exchange ruling at the end of the reporting period.
All differences are taken to the statement of profit or loss and
other comprehensive income.
Exchange differences arising on the settlement
of monetary items and on the retranslation of monetary items are
included in the statement of comprehensive income for the
period.
The assets and liabilities of the Group are
expressed in US Dollars using exchange rates prevailing at the
balance sheet date. Income and expense items are translated at the
average exchange rates for the period. Exchange differences
arising, if any, are classified as other comprehensive income and
are transferred to the Group's translation reserve.
2.8
Current and deferred taxation
The tax expense for the period comprises current
and deferred tax. Tax is recognised in the statement of
comprehensive income, except that a charge attributable to an item
of income or expense recognised as other comprehensive income or to
an item recognised directly in equity is also recognised in other
comprehensive income or directly in equity respectively.
The current income tax charge is calculated on
the basis of tax rates and laws that have been enacted or
substantively enacted by the reporting date in the UK where
the Group operates and generates taxable
income.
Deferred tax balances are recognised in respect
of all temporary differences that have originated but not reversed
by the reporting date, except:
- The
recognition of deferred tax assets is limited to the extent that it
is probable that they will be recovered against the reversal of
deferred tax liabilities or other future taxable profits;
and
- Any
deferred tax balances are reversed if and when all conditions for
retaining associated tax allowances have been met.
Deferred tax balances are not recognised in
respect of permanent differences except in respect of business
combinations, when deferred tax is recognised on the differences
between the fair values of assets acquired and the future tax
deductions available for them and the differences between the fair
values of liabilities acquired and the amount that will be assessed
for tax. Deferred income tax is determined using tax rates and laws
that have been enacted or substantively enacted by the reporting
date.
2.9
Property, plant and equipment
Items of property, plant and equipment are
stated at historical cost less accumulated depreciation.
Depreciation is provided at the following annual
rates in order to write off each asset over its estimated useful
life.
|
Plant and equipment
|
-
|
20 per cent straight-line
|
The assets' residual values and useful lives are
reviewed, and adjusted if appropriate, at each balance sheet
date.
Notes to the consolidated financial statements
(continued)
2. Accounting
policies (continued)
2.10 Intangible
assets
Intangible assets that are acquired by the Group
are stated at cost less accumulated amortisation and accumulated
impairment losses.
Amortisation is charged to the administrative
expenses in the statement of profit or loss and other comprehensive
income on a straight-line basis over the estimated useful lives of
intangible assets unless such lives are indefinite. Intangible
assets with an indefinite useful life and goodwill are
systematically tested for impairment at each balance sheet
date.
Intangible assets are amortised from the date
they are available for use. The estimated useful lives are as
follows on a straight-line basis:
|
Intellectual property and patents
|
-
|
Length of the
trademark/patent
|
The estimated useful lives are based upon
management's best estimate of the expected life of the asset.
Useful lives are reconsidered if circumstances relating to the
asset change or if there is an indication that the initial estimate
requires revision.
2.11
Inventories
Inventories are initially recognised at cost,
and subsequently at the lower of cost and net realisable value.
Cost comprises all costs of purchase, costs of conversion and other
costs incurred in bringing the inventories to their present
location and condition.
Weighted average cost is used to determine the
cost of ordinarily interchangeable items.
2.12 Cash and cash
equivalents
Cash and cash equivalents comprise cash at bank
and in hand and short term highly liquid deposits which are subject
to an insignificant risk of changes in value.
Notes to the consolidated financial statements
(continued)
2. Accounting policies
(continued)
2.13 Financial
assets
The Group classifies its financial assets at
amortised cost. Management determines the classification of
its financial assets at initial recognition.
The Group's financial assets held at amortised
cost comprise trade and other receivables and cash and cash
equivalents in the consolidated statement of financial
position.
These assets are non-derivative financial
assets with fixed or determinable payments that are not quoted in
an active market. They arise principally through the
provision of goods and services to customers (e.g. trade
receivables), but also incorporate other types of financial assets
where the objective is to hold their assets in order to collect
contractual cash flows and the contractual cash flows are solely
payments of the principal and interest.
They are initially recognised at fair value
plus transaction costs that are directly attributable to their
acquisition or issue and are subsequently carried at amortised cost
using the effective interest rate method, less provision for
impairment.
Impairment provisions for trade receivables are
recognised based on the simplified approach within IFRS 9 using the
lifetime ECLs. During this process the probability of the
non-payment of the trade receivables is assessed. This probability
is then multiplied by the amount of the expected loss arising from
default to determine the lifetime ECL for the trade receivables.
For trade receivables, which are reported net; such provisions are
recorded in a separate provision account with the loss being
recognised within administrative expenses in the consolidated
statement of comprehensive income. On confirmation that the trade
receivable will not be collectable, the gross carrying value of the
asset is written off against the associated provision.
2.14 Financial
liabilities
The Group measures its financial
liabilities at amortised cost. All financial liabilities are
recognised in the statement of financial position when the Group
becomes a party to the contractual provision of the
instrument.
The Group's financial liabilities held at
amortised cost comprise trade payables and other short-dated
monetary liabilities, and borrowings in the consolidated statement
of financial position.
Trade payables and other short-dated
monetary liabilities are initially recognised at fair value and
subsequently carried at amortised cost using the effective interest
rate method.
Borrowings are initially recognised
at fair value net of any transaction costs directly attributable to
the issue of the instrument. Such interest-bearing
liabilities are subsequently measured at amortised cost using the
effective interest rate method, which ensures that any interest
expense over the period to repayment is at a constant rate on the
balance of the liability carried in the consolidated statement of
financial position.
For the purposes of each financial
liability, interest expense includes initial transaction costs and
any premium payable on redemption, as well as any interest or
coupon payable while the liability is outstanding.
Unless otherwise indicated, the
carrying values of the Group's financial liabilities measured at
amortised cost represents a reasonable approximation of their fair
values.
Notes to the consolidated financial statements
(continued)
2. Accounting policies
(continued)
2.15 Impairment of
assets
Assets that are subject to depreciation or
amortisation are assessed at each reporting date to determine
whether there is any indication that the assets are
impaired.
Where there is any indication that an asset may
be impaired, the carrying value of the asset is tested for
impairment. An impairment loss is recognised for the amount by
which the asset's carrying amount exceeds its recoverable amount.
The recoverable amount is the higher of an asset's fair value less
costs to sell and value in use. Non-financial assets that have been
previously impaired are reviewed at each reporting date to assess
whether there is any indication that the impairment losses
recognised in prior periods may no longer exist or may have
decreased.
2.16 Equity
instruments
Equity is the residual interest in
the assets of the Company after deducting all liabilities and
comprises the following:
·
"Share capital" represents the nominal value of
equity shares;
·
"Share premium" represents the excess value of
equity shares above the nominal value;
·
"Share-based payment reserve" represents the
cumulative fair value of options;
·
"Capital contribution reserve" represents non-cash
contributions from equity holders;
·
"Accumulated losses" represents retained earnings
less retained losses;
·
"Translation reserve" represents the Cumulative
gains and losses on translating the net assets of the Company to
the presentation currency of the Group" and
·
"Non-controlling interests" represents the
cumulative net profits/(losses) in relation to non-controlling
interests.
2.17 Convertible loan
notes
Convertible loan note instruments issued by the
Group are assessed to whether the transaction price relates to both
the underlying financial instrument and the warrants issued
representing the same economic arrangement, and therefore fair
value of the whole arrangement. The Group assesses whether the
underlying financial instrument (loan notes) and the conversion
feature should be classified as a liability or equity instrument.
As part of this assessment, the Group considers whether the
conversion feature is closely related to the host contract,
requiring a separate assessment of the host contract and the
conversion feature. It was determined that the conversion feature
was not closely related to the host contract, meeting the criteria
for recognition as a separate embedded derivative.
Loan note: It was determined that the Group does
not have an unconditional right to avoid delivering cash or another
financial asset to settle the contractual obligation, meeting the
criteria to be recognised as a financial liability.
Conversion feature: There is an obligation to
convert the loan notes into variable number of ordinary shares of
MicroSalt Inc. on conversion events. The conversion feature is at
market price as there is no discount against future equity
placement offered. Therefore, the conversion feature is not a
derivative because the value of the conversion feature does not
change in response to the share price, and as such the conversion
feature is a financial liability.
Therefore, the fair value of the overall
transaction price is initially recognised as a financial liability
and subsequently measured at amortised cost.
Notes to the consolidated financial statements
(continued)
2. Accounting policies
(continued)
2.18 Share-based
payments
Equity-settled share-based payments
are measured at fair value at the date of grant by reference to the
fair value of the equity instruments granted. The fair value
determined at the grant date is expensed on a straight-line basis
over the vesting period with a corresponding adjustment to equity.
The amount recognised as an expense is adjusted to reflect the
number of awards for which the related service and non-market
performance conditions are expected to be met.
Non-market vesting conditions are
taken into account by adjusting the number of equity instruments
expected to vest at each statement of financial position date so
that, ultimately, the cumulative amount recognised over the vesting
period is based on the number of options that eventually vest.
Market vesting conditions are factored into the fair value of the
options granted. The cumulative expense is not adjusted for failure
to achieve a market vesting condition.
The fair value of the award also
takes into account non-vesting conditions. These are either factors
beyond the control of either party (such as a target based on an
index) or factors which are within the control of one or other of
the parties (such as the Group keeping the scheme open or the
employee maintaining any contributions required by the
scheme).
When the terms and conditions of
equity-settled share-based payments at the time they were granted
are subsequently modified, the fair value of the share-based
payment under the original terms and conditions and under the
modified terms and conditions are both determined at the date of
the modification. Any excess of the modified fair value over the
original fair value is recognised over the remaining vesting period
in addition to the fair value of the original share-based
payment at date of grant.
3. Significant
accounting judgements, estimates and assumptions
The preparation of the financial statements
requires the use of certain critical accounting estimates. It also
requires the Group management to exercise
judgement and use assumptions in applying the
Group's accounting policies. The resulting accounting
estimates calculated using these judgements and assumptions will,
by definition, seldom equal the related actual results but are
based on historical experience and expectations of future events.
Management believe that the estimates utilised in preparing the
financial statements are reasonable and prudent.
Estimates and judgements are continually
evaluated based on historical experience and other factors,
including expectations of future events that are believed to be
reasonable under the circumstances. In the future, actual
experience may differ from these estimates and assumptions. The
judgements and key sources of estimation uncertainty that have a
significant effect on the amounts recognised in the financial
statements are discussed below:
Key accounting estimates and
judgements
Share-based payments
In order to calculate the value of employee
share options as required by IFRS 2, the Group makes estimates
principally relating to the assumptions used in its option-pricing
model. This is a key estimate used to value the share options in
issue at the balance sheet date.
Notes to the consolidated financial statements
(continued)
4. Revenue from contracts
with customers
All Group revenue was generated from the sale of
goods in the USA and recognised at the date the goods were
delivered. 4 customers make up 10% or more of revenue in the period
ended 31 December 2023 (2023: 3).
|
31 Dec
|
|
31 Dec
|
|
2023
|
|
2022
|
|
US$'000
|
|
US$'000
|
|
|
|
|
Customer 1
|
132
|
|
159
|
Customer 2
|
107
|
|
-
|
Customer 3
|
66
|
|
180
|
Customer 4
|
29
|
|
145
|
|
|
|
|
5. Other operating
income
|
|
|
31 Dec
|
|
31 Dec
|
|
2023
|
|
2022
|
|
US$'000
|
|
US$'000
|
|
|
|
|
R&D expenditure tax credit
|
48
|
|
23
|
Other income
|
72
|
|
7
|
|
120
|
|
30
|
6. Segmental
reporting
Factors that management used to identify the
Group's reportable segments:
The Chief Operating Decision Maker ("CODM") has
been identified as the Directors. The CODM reviews the Group's
internal reporting in order to assess performance and allocate
resources. The CODM has determined that there is one single
operating segment, the development and sale of low sodium salt and
snack foods.
7. Operating
loss
|
31 Dec
|
|
31 Dec
|
|
2023
|
|
2022
|
|
US$'000
|
|
US$'000
|
|
|
|
|
Amortisation of intangible assets
|
6
|
|
2
|
Research and development expense
|
81
|
|
95
|
Trade debtor written off
|
-
|
|
15
|
Share-based payment expense
|
572
|
|
379
|
Inventory recognised as an expense
|
81
|
|
441
|
Expected credit losses
|
(3)
|
|
11
|
Notes to the consolidated financial statements
(continued)
8. Auditors'
remuneration
During the year the Group obtained the
following services from the Group's auditors:
|
31 Dec
|
|
31 Dec
|
|
2023
|
|
2022
|
|
US$'000
|
|
US$'000
|
|
|
|
|
Fees payables for the audit of the Group and
Company's annual accounts
|
45
|
|
-
|
Fees payables for all other pre-IPO non-audit
services
|
208
|
|
-
|
|
253
|
|
-
|
9. Employees and
directors
|
2023
|
|
2022
|
|
US$'000
|
|
US$'000
|
|
|
|
|
Wages and salaries
|
276
|
|
123
|
Social security costs
|
72
|
|
26
|
Share-based payment expense
|
572
|
|
379
|
|
920
|
|
528
|
The average monthly number of employees and
Directors during the year was as follows:
|
2023
|
|
2022
|
|
Number
|
|
Number
|
|
|
|
|
Management and administration
|
5
|
|
3
|
|
5
|
|
3
|
Directors' remuneration is as
follows:
|
2023
|
|
2022
|
|
US$'000
|
|
US$'000
|
|
|
|
|
Directors' emoluments,
including salaries and fees
|
221
|
|
123
|
Social security costs
|
18
|
|
26
|
Share-based payment expense
|
572
|
|
262
|
|
811
|
|
411
|
Key management personnel include all of the
Directors, who together have authority and responsibility for
planning, directing, and controlling the activities of the
Group's business. There are no key
management personnel other than the Directors of
the Group.
The remuneration of the highest paid Director
who served during the year was Rick Guiney which consisted of base
salary of US$150,000 (2022: US$150,000), paid by MicroSalt
Inc.
Notes to the consolidated financial statements
(continued)
10. Finance expense
|
31 Dec
|
|
31 Dec
|
|
2023
|
|
2022
|
|
US$'000
|
|
US$'000
|
Finance costs:
|
|
|
|
Interest on convertible loans
|
131
|
|
67
|
|
131
|
|
67
|
11. Taxation
Analysis of tax
expense
No liability to UK corporation tax arose on
ordinary activities for the year ended 31 December 2023 or for the
year ended 31 December 2022.
Factors
affecting the tax expense
The tax assessed for the year is lower than the
standard rate of corporation tax in the UK. The difference is
explained below:
|
31 Dec
|
|
31 Dec
|
|
2023
|
|
2022
|
|
US$'000
|
|
US$'000
|
|
|
|
|
Loss on ordinary activities before
tax
|
(3,479)
|
|
(2,479)
|
|
|
|
|
Tax using the Group's domestic tax
rates
|
(817)
|
|
(471)
|
|
|
|
|
Effects of:
|
|
|
|
Deferred tax adjustment - remeasurement of
current year losses at future tax rate
|
(52)
|
|
-
|
Unutilised tax losses carried forward
|
869
|
|
471
|
|
|
|
|
Total taxation credit
|
-
|
|
-
|
The main rate of UK corporation tax for the year ended 31 December
2022 and up to 1 April 2023 was 19%. From 1 April 2023, the main
rate of UK corporation tax increased to 25%, resulting in an
effective tax rate of 23.5% for the year ended 31 December
2023.
Notes to the consolidated financial statements
(continued)
12. Basic and diluted loss per
share
Basic and diluted loss per share is calculated
by dividing the result attributable to equity holders by the
weighted average number of ordinary shares in issue. Loss per share
is presented based on the number of shares outstanding in the
Company.
|
31 Dec
|
|
31 Dec
|
|
2023
|
|
2022
|
|
|
|
|
Loss used in calculating basic and diluted loss
per share (US$)
|
(3,479,000)
|
|
(1,940,000)
|
Weighted average number of shares
|
8,895,498
|
|
11,643
|
Basic and diluted loss per share
(US$)
|
(0.39)
|
|
(166.61)
|
The diluted earnings per share is identical to
the basic loss per share as the exercise of warrants and options
would be anti-dilutive.
The weighted average number of shares for both
periods presented has been adjusted for the effect of the 3200:1
share subdivision and subsequent 1:520 share
consolidation.
13. Intangible assets
|
Patent
|
|
Trademark
|
|
Total
|
|
US$'000
|
|
US$'000
|
|
US$'000
|
Cost
|
|
|
|
|
|
At 1 January 2022
|
38
|
|
-
|
|
38
|
Additions
|
116
|
|
-
|
|
116
|
At 31 December 2022
|
154
|
|
-
|
|
154
|
|
|
|
|
|
|
Amortisation
|
|
|
|
|
|
At 1 January 2022
|
5
|
|
-
|
|
5
|
Charge for the period
|
2
|
|
-
|
|
2
|
At 31 December 2022
|
7
|
|
-
|
|
7
|
|
|
|
|
|
|
Net book amount
|
|
|
|
|
|
At 31 December 2022
|
147
|
|
-
|
|
147
|
|
|
|
|
|
|
Cost
|
|
|
|
|
|
At 1 January 2023
|
154
|
|
-
|
|
154
|
Additions
|
149
|
|
31
|
|
180
|
At 31 December 2023
|
303
|
|
31
|
|
334
|
|
|
|
|
|
|
Amortisation
|
|
|
|
|
|
At 1 January 2023
|
7
|
|
-
|
|
7
|
Charge for the period
|
6
|
|
-
|
|
6
|
At 31 December 2023
|
13
|
|
-
|
|
13
|
|
|
|
|
|
|
Net book amount
|
|
|
|
|
|
At 31 December 2023
|
290
|
|
31
|
|
321
|
Notes to the consolidated financial statements
(continued)
14. Property, plant and
equipment
The Group had no items of property, plant and
equipment in the year ended 31 December 2022.
|
Plant &
equipment
|
|
Total
|
|
US$'000
|
|
US$'000
|
Cost
|
|
|
|
At 1 January 2023
|
-
|
|
-
|
Additions
|
9
|
|
9
|
At 31 December 2023
|
9
|
|
9
|
|
|
|
|
|
|
|
|
Depreciation
|
|
|
|
At 1 January 2023
|
-
|
|
-
|
Charge for the period
|
1
|
|
1
|
At 31 December 2023
|
1
|
|
1
|
|
|
|
|
Net book amount
|
|
|
|
At 31 December 2023
|
8
|
|
8
|
15. Inventory
|
2023
|
|
2022
|
|
US$'000
|
|
US$'000
|
|
|
|
|
Raw materials
|
279
|
|
15
|
Finished goods and goods for resale
|
289
|
|
193
|
|
568
|
|
208
|
Notes to the consolidated financial statements
(continued)
16. Trade and other
receivables
|
2023
|
|
2022
|
|
US$'000
|
|
US$'000
|
|
|
|
|
Trade receivables
|
224
|
|
116
|
Other receivables
|
307
|
|
80
|
Prepayments
|
728
|
|
25
|
|
1,259
|
|
221
|
Trade receivables are amounts due from customers
for goods sold in the ordinary course of business. They are
generally due for settlement immediately or within 30 days for
certain credit customers and therefore are all classified as
current. Trade receivables are non-interest bearing. The carrying
amount of trade and other receivables approximates fair
value.
Prepayments include US$690,000 of deferred costs
in relation to the IPO of the Company on AIM, which completed 1
February 2024.
Analysis of trade receivables based on age of
invoices:
|
< 30
days past
due
US$'000
|
31 - 60 days past
due
US$'000
|
61 -90 days past
due
US$'000
|
> 90
days past
due
US$'000
|
Total
gross
US$'000
|
ECL
US$'000
|
Total net
US$'000
|
31 December 2023
|
145
|
10
|
44
|
33
|
232
|
(8)
|
224
|
31 December 2022
|
9
|
7
|
58
|
53
|
127
|
(11)
|
116
|
The Group applies the IFRS 9 simplified approach
to measuring expected credit losses (ECL) which uses a lifetime
expected loss allowance for all trade receivables. The ECL balance
has been determined as US$8,000 (2022: US$11,000) based on
historical data available to management in addition to forward
looking information utilising management knowledge. The ECL is
based on 90% of trade receivables over 60 days past due being
recoverable and therefore an ECL of 10% of trade receivables has
been recognised. Based on the analyses performed there is no
material impact on the transition to ECL from previous methods of
estimating the provision for doubtful accounts.
17. Cash and cash
equivalents
|
2023
|
|
2022
|
|
US$'000
|
|
US$'000
|
|
|
|
|
Cash at bank
|
117
|
|
91
|
|
117
|
|
91
|
Notes to the consolidated financial statements
(continued)
18. Trade and other payables
|
31 Dec
|
|
31 Dec
|
|
2023
|
|
2022
|
|
US$'000
|
|
US$'000
|
Amounts falling due in one year:
|
|
|
|
Trade payables
|
974
|
|
142
|
Other payables
|
667
|
|
1
|
Accruals
|
104
|
|
22
|
|
1,745
|
|
165
|
Other payables include amounts owed to related
parties (see note 25).
19. Borrowings
|
31 Dec
|
|
31 Dec
|
|
2023
|
|
2022
|
|
US$'000
|
|
US$'000
|
Current
|
|
|
|
Convertible loan notes
|
2,524
|
|
170
|
|
2,524
|
|
170
|
On 1 June 2022, the Group issued convertible
loan notes ("CLNs") with a principal amount of US$2,000,000 of
which US$2,000,000 was drawn and outstanding at 31 December 2023
(2022: US$141,000). The Group issued further CLNs on 1 March 2023
and 1 October 2023, with principal amounts of US$2,000,000 each, of
which US$909,000 and US$Nil were drawn down at 31 December 2023,
respectively.
The CLNs incur interest of 10% per annum and are
repayable four years after commencement or can be converted into
ordinary shares of MicroSalt Inc. upon certain conversion events at
the option of the noteholder. During the year ended 31 December
2023, US$500,000 (2022: US$409,000) was converted into ordinary
shares of MicroSalt Inc.
Notes to the consolidated financial statements
(continued)
20. Share capital
|
31 Dec
|
|
31 Dec
|
|
31 Dec
|
|
31 Dec
|
|
2023
|
|
2023
|
|
2022
|
|
2022
|
|
Shares
|
|
US$
|
|
Shares
|
|
US$
|
Allotted, called up and fully paid
|
|
|
|
|
|
|
|
Opening number of £0.01 ordinary
shares
|
1,892
|
|
26
|
|
1,892
|
|
26
|
Subdivision into
£0.000003125 ordinary shares
|
6,052,508
|
|
-
|
|
-
|
|
-
|
Issue of ordinary
share
|
1
|
|
-
|
|
-
|
|
-
|
Consolidation of
shares into £0.001625 ordinary shares
|
(6,042,758)
|
|
-
|
|
-
|
|
-
|
Issue of ordinary shares
|
35,234,086
|
|
72,900
|
|
-
|
|
-
|
Closing number of
£0.001625 ordinary shares
|
35,245,729
|
|
72,296
|
|
1,892
|
|
26
|
All issues are for cash unless otherwise
stated.
On 15 June 2023, the Company performed a share
subdivision to issue 3,200 new ordinary shares for every existing 1
share. Subsequently, on 30 September 2023, the Company performed a
share consolidation to issue 1 share for every existing 520
shares.
|
31 Dec
|
|
31 Dec
|
|
2023
|
|
2022
|
|
US$'000
|
|
US$'000
|
Share
premium
|
|
|
|
Opening balance
|
1,121
|
|
1,121
|
Issue of shares
|
2,452
|
|
-
|
Cancellation of share premium
|
(3,573)
|
|
-
|
Closing balance
|
-
|
|
1,121
|
On 29 June 2023, the Company cancelled the share
premium account of the Company, and the amount of the share premium
account was transferred to distributable reserves. The Cancellation
of Reserve was carried out by way of the solvency statement
procedure under section 641(1)(a) of the Companies Act.
Notes to the consolidated financial statements
(continued)
21. Share-based payments
The Group operates an equity settled
share-based remuneration scheme for employees. Options are granted
for nil consideration and carry no dividend or voting rights. The
terms and conditions of the grants are detailed below:
Date of grant
|
No. of
options
('000)
|
Exercise
price
|
Vesting
conditions
|
Expected life of
options
|
Share price at grant
date
|
Expected option
life
|
Risk free interest
rate
|
1 January 2022
|
56,000
|
US$0.2500
|
Time-based1
|
3
years
|
US$1.00
|
1 year
|
0.87%
|
24 February 2022
|
1,000,000
|
US$0.2500
|
Time-based2
|
4
years
|
US$1.00
|
3 years
|
1.06%
|
1 August 2022
|
400,000
|
US$0.3225
|
Time-based3
|
3
years
|
US$1.29
|
3 years
|
2.87%
|
27 October 2022
|
804,800
|
US$0.3225
|
Exit
event5
|
3
years
|
US$1.29
|
3 years
|
3.45%
|
18 November 2022
|
1,600,000
|
US$0.5450
|
Time-based2
|
5
years
|
US$2.18
|
3 years
|
3.26%
|
1100% of the share options vest in one annual instalment 12
months after the grant date.
22.78% of the share options vest in equal monthly instalments
over 36 months from the grant date.
333.33% of the share options vest 12 months after the grant
date, 33.33% of the share options vest 24 months after the grant
date and the remaining 33.33% of share options vest 36 months after
the grant date.
450% of the share options vest six months after the grant date
and 50% of the share options vest 12 months after the grant
date.
5These options vest on an exit event, such as a sale, takeover
or IPO.
The number of options and exercise
price above have been adjusted for the effect of a 3200:1 share
subdivision and subsequent 1:520 share consolidation which occurred
in the year.
All options granted have an expected
volatility of 80%.
On 30 September 2023, all of the
options held with MicroSalt Inc. were cancelled and reissued with
the Company on the same terms as the existing agreements. As such,
the fair value of the options has not increased as a result of the
modification and therefore no adjustment has been made to
share-based payment expense in the year.
Details of the number of share options granted,
exercised, lapsed and outstanding at the end of each period as well
as the weighted average exercise prices in US$ ("WAEP") are as
follows:
|
2023
No.
|
|
2023
WAEP
|
|
2022
No.
|
|
2022
WAEP
|
Outstanding at the
beginning of the year
|
6,710,684
|
|
0.37
|
|
1,969,884
|
|
0.07
|
Granted during the
year
|
-
|
|
-
|
|
4,740,800
|
|
0.42
|
Outstanding at the end
of the year
|
6,710,684
|
|
0.37
|
|
6,710,684
|
|
0.37
|
Exercisable at the end
of the year
|
4,569,024
|
|
0.37
|
|
2,036,376
|
|
0.32
|
The number of share options and WAEP have been
adjusted in both periods presented for the effect of the 3200:1
share subdivision and subsequent 1:520 share
consolidation.
Notes to the consolidated financial statements
(continued)
22. Non-controlling
interests
MicroSalt Inc. is a 91.75% owned
subsidiary as at 31 December 2023 and had historically been
considered a material non-controlling interests ("NCI"). The
Company no longer considers the NCI to be material to the Company,
and therefore no NCI has been disclosed for the year ended 31
December 2023.
23. Financial instruments
The Group's financial instruments comprise cash
and cash equivalents, trade and other receivables, trade and other
payables, accruals, and convertible loan note liabilities, that
arise directly from its operations.
Financial
assets
|
|
|
31 Dec
|
|
31 Dec
|
|
2023
|
|
2022
|
|
US$'000
|
|
US$'000
|
|
|
|
|
Trade receivables
|
232
|
|
116
|
Other receivables
|
990
|
|
80
|
Cash at bank
|
117
|
|
91
|
|
1,339
|
|
287
|
Financial
liabilities
|
|
|
31 Dec
|
|
31 Dec
|
|
2023
|
|
2022
|
|
US$'000
|
|
US$'000
|
|
|
|
|
Trade payables
|
974
|
|
142
|
Other payables
|
667
|
|
1
|
Accruals
|
104
|
|
22
|
Convertible loan note liabilities
|
2,524
|
|
170
|
|
4,269
|
|
335
|
The carrying values of the Group's financial
liabilities measured at amortised cost represents a reasonable
approximation of their fair values.
Financial risk
management
The Group is exposed through its operation to
the following financial risks: credit risk, interest rate risk,
foreign exchange risk and liquidity risk. Risk management is
carried out by the Directors. The Group uses financial instruments
to provide flexibility regarding its working capital requirements
and to enable it to manage specific financial risks to which it is
exposed.
The Group finances its operations through a
mixture of debt finance, cash and liquid resources and various
items such as trade debtors and trade payables which arise directly
from the Group's operations.
a) Foreign exchange
risk
The Group operates internationally and is
exposed to currency risk arising on cash and cash equivalents,
receivables and payables denominated in a currency other than the
respective functional currencies of the Group entities, which are
primarily US Dollars and Sterling. The Group's manages foreign
currency risk by, where possible, settling liabilities denominated
in a currency other than its functional currency with cash already
denominated in that currency.
Notes to the
consolidated financial statements (continued)
23. Financial instruments
(continued)
The carrying amounts of the Group's foreign
currency denominated monetary assets and monetary liabilities at
the reporting date are as follows:
|
31 Dec
|
|
31 Dec
|
|
2023
|
|
2022
|
|
US$'000
|
|
US$'000
|
Net foreign
currency liabilities
|
|
|
|
GBP
|
208
|
|
-
|
Sensitivity
analysis
A 10% strengthening of sterling against the
Group's primary currencies at 31 December 2023 would have
decreased equity and profit or loss by the amounts shown
below:
|
31 Dec
|
|
31 Dec
|
|
2023
|
|
2022
|
|
US$'000
|
|
US$'000
|
Effect on equity
|
21
|
|
-
|
Effect on profit or loss
|
21
|
|
-
|
A 10% weakening of sterling against the Group's
primary currencies at 31 December 2023 would have an
equal but opposite effect on the amounts shown above.
b) Interest rate
risk
Interest rate risk is the risk that the fair
value of future cash flows associated with the instrument will
fluctuate due to changes in market interest rates. The Group's only
interest-bearing borrowings are at a fixed interest rate of 10%,
therefore interest rate risk exposure for the Group is
minimal.
It is the Group's policy to settle payables
within the credit terms allowed and the Group does therefore not
incur interest on overdue balances.
c) Credit
risk
Credit risk is the risk of financial loss to
the Group if a customer or counterparty to a financial instrument
fails to meet its contractual obligations. In order to minimise the
risk, the Group endeavours only to deal with companies which are
demonstrably creditworthy and this, together with the aggregate
financial exposure, is continuously monitored. The maximum exposure
to credit risk is the carrying value of its financial receivables,
trade and other receivables and cash and cash equivalents as
disclosed in the note above.
The receivables age analysis is evaluated on a
regular basis for potential doubtful debts, considering historic,
current and forward-looking information. No impairments to trade
receivables, have been made to date. Further disclosures regarding
trade and other receivables are provided within note 16.
Credit risk also arises on cash and cash
equivalents and deposits with banks and financial institutions. For
banks and financial institutions, only independently rated parties
with minimum rating "B+" are accepted. Currently the financial
institution whereby the Group holds significant levels of cash is
JP Morgan Chase Bank, N.A. which is rated AA-.
Notes to the
consolidated financial statements (continued)
23. Financial instruments
(continued)
d) Liquidity risk
The Group seeks to maintain sufficient cash
balances. Management review cash flow forecasts on a regular basis
to determine whether the Group has sufficient cash reserves to meet
future working capital requirements and to take advantage of
business opportunities.
A maturity analysis of the Group's total
liabilities is shown below:
|
Group
|
|
31 Dec
|
|
31 Dec
|
|
2023
|
|
2022
|
|
US$'000
|
|
US$'000
|
Within 1 year:
|
|
|
|
Trade and other payables
|
1,641
|
|
143
|
Accruals
|
104
|
|
22
|
Later than 1 year and
less than 5 years
|
1,745
|
|
165
|
|
|
|
|
Convertible loan note liabilities
|
2,524
|
|
170
|
After 5 years
|
2,524
|
|
170
|
|
|
|
|
Total including interest cash flows
|
4,269
|
|
335
|
Less: interest cash flows
|
(131)
|
|
(67)
|
Total principal cash flows
|
4,138
|
|
268
|
24. Related party
disclosures
Key management personnel remuneration is
disclosed in note 9 above.
|
|
Transaction amount
|
|
Balance owed
|
Related party
relationship
|
Type of transaction
|
2023
US$'000
|
|
2022
US$'000
|
|
2023
US$'000
|
|
2022
US$'000
|
Tekcapital
plc
|
Convertible loan notes
issued
|
2,723
|
|
1,652
|
|
2,524
|
|
170
|
Tekcapital Europe
Ltd
|
Related party loan
|
590
|
|
52
|
|
642
|
|
52
|
Notes to the
consolidated financial statements (continued)
25. Changes in liabilities from
financing activities
|
At 1 January
2022
US$'000
|
|
Financing cash flows
US$'000
|
|
Interest
US$'000
|
|
Non-cash changes
US$'000
|
|
At 31 December 2022
US$'000
|
Convertible loan notes
|
860
|
|
1,652
|
|
67
|
|
(2,409)
|
|
170
|
Total
liabilities from financing activities
|
860
|
|
1,652
|
|
67
|
|
(2,409)
|
|
170
|
|
At 1 January
2023
US$'000
|
|
Financing cash flows
US$'000
|
|
Interest
US$'000
|
|
Non-cash changes
US$'000
|
|
At 31 December 2023
US$'000
|
Convertible loan notes
|
170
|
|
2,723
|
|
131
|
|
(500)
|
|
2,524
|
Total
liabilities from financing activities
|
170
|
|
2,723
|
|
131
|
|
(500)
|
|
2,524
|
The non-cash changes in both years relate to
capital contributions from the ultimate controlling
party.
26. Events after the reporting
date
On 1 February 2024, the Company completed its
IPO on the AIM Market of London Stock Exchange plc raising
approximately £3.1m (US$3.9m).